Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil may cause initial facial puffiness and fine lines, but effects often diminish over time. Some users report no significant aging effects, while others switch to alternatives like dermarolling.

A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Latisse (bimatoprost) is discussed as a potential treatment for hair growth due to difficulty obtaining PGE2. Users also mention concerns about sourcing reliable products from China.

The conversation discusses using stemoxydine as a carrier for RU58841 and the search for affordable, premixed PG+E. Minoxidil is considered as an alternative, but simplicity is preferred.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The conversation discusses finding a PG-free solvent for dissolving RU58841 in the UK, with glycerin suggested as a potential alternative. Water is also mentioned as a possible option.

Mixing PGE2 and sandalwood oil for hair regrowth. Suggested formula: 1 drop sandalore to 30 ml carrier oil.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses a community called PHG, which focuses on experimental hair loss treatments and scientific approaches to hair regrowth. It mentions treatments like Minoxidil, finasteride, and RU58841, and highlights interest in new treatments like Setipripant, Histogen, and Replicel.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

The conversation discusses the use of ethanol and propylene glycol (PG) in topical solutions for hair loss treatments, specifically Minoxidil. The user dislikes the texture of PG and questions the ideal ratio and necessity of PG in these solutions.

The conversation discusses using propanediol as an alternative to glycerin in PG-free minoxidil for better absorption. The user also plans to try nanoxidil, which may absorb more easily due to its smaller molecule size.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.